GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiVictriX Therapeutics PLC (LSE:BVX) » Definitions » Loans Receivable

BiVictriX Therapeutics (LSE:BVX) Loans Receivable : £0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is BiVictriX Therapeutics Loans Receivable?

BiVictriX Therapeutics's Loans Receivable for the quarter that ended in Jun. 2024 was £0.00 Mil.


BiVictriX Therapeutics Loans Receivable Historical Data

The historical data trend for BiVictriX Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiVictriX Therapeutics Loans Receivable Chart

BiVictriX Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

BiVictriX Therapeutics Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

BiVictriX Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


BiVictriX Therapeutics Loans Receivable Related Terms

Thank you for viewing the detailed overview of BiVictriX Therapeutics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


BiVictriX Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Alderley Edge, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG
BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilizes Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia. The Group has one reportable segment, being the development of pharmaceutical products within the United Kingdom.

BiVictriX Therapeutics Headlines

No Headlines